Rapamycin decreases PD-L1 expression in lung tumors in vivo.

Slides:

Advertisements

Similar presentations

Immunohistochemical staining for RXR subtypes within benign and endometrioid endometrial carcinoma. Immunohistochemical staining for RXR subtypes within.

Advertisements

Supplementary Table 1 Akt2 is required for NNK-induced lung tumorigenesis but not for urethane-induced lung tumorigenesis while Akt3 may act as a tumor.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Effects of SC144 on in vivo ovarian tumor.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. A.

NICD1 immunohistochemical staining in normal and tumor tissue.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

Expression of mutant EGFR and downstream signaling components in tumors of mice at survival endpoint. Expression of mutant EGFR and downstream signaling.

Combined HDAC and mTOR inhibitors kill NF1-mutant malignancies in vitro and in vivo. Combined HDAC and mTOR inhibitors kill NF1-mutant malignancies in.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

NOX1-deficient mice do not respond to GKT771 and exhibit reduced B16-F10 tumor growth associated with decreased production of angiogenic factors and minor.

BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR signaling in the NNK-treated mice. BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR.

Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:

NOX1-deficient mice do not respond to GKT771 and exhibit reduced tumor growth, angiogenesis, and lymphangiogenesis. NOX1-deficient mice do not respond.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Expression profile of RSPO1 and 2 in gastric cancer.

coTCRcys-transduced T cells control tumor growth in vivo.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

In vivo thrombosis of tumor vasculature.

Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.

Vandetanib decreases tumor incidence and accumulation of HIF-2α, expression of c-Myc and growth factor receptors in the lung of hypoxic mice. Vandetanib.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

EMT gene expression patterns of M-Wnt and E-Wnt cells in vitro and in vivo. EMT gene expression patterns of M-Wnt and E-Wnt cells in vitro and in vivo.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

HCCs with overexpression of biliary/progenitor marker genes.

In vivo efficacy of targeted EDVTM in an orthotopic neuroblastoma mouse model with high EGFR protein levels. In vivo efficacy of targeted EDVTM in an orthotopic.

N-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. n-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. HEC-1-A.

The AKT–mTOR pathway controls PD-L1 protein expression.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

CRA inhibits the growth of human tumor xenografts in vivo.

HMQ1611 inhibited breast tumor growth in mice.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant tumors. Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant.

Effect of CDV on human SF7796 xenografts in vivo.

YH25448 less suppresses WT EGFR than osimertinib in vivo.

Expression of PCNA, K10, and K5 in skin lesions from Stat3+/−:HPV8 and Stat3+/+:HPV8 mice. Expression of PCNA, K10, and K5 in skin lesions from Stat3+/−:HPV8.

The effect of a DIO regimen ± EPA+DHA supplementation on tumor growth.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Pomalidomide decreases fibrosis in the lesion areas of the pancreas of KC mice. Pomalidomide decreases fibrosis in the lesion areas of the pancreas of.

Histology (H&E; original magnification, ×100 for B-2P/C-12P/C-64P and ×40 for C-10P; top) of small-sized lung adenocarcinomas and immunohistochemical staining.

Increased expression of angiogenic factors and inflammatory cytokines in mice exposed to hypoxia. Increased expression of angiogenic factors and inflammatory.

In vivo effects of TTFields on intradermal tumors in mice.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Effects of ZOL treatment on pulmonary metastases.

Inhibition of spontaneous pulmonary metastasis and prolonged survival after removal of primary tumor and intratracheal delivery of rAAV2/5-VAS. Inhibition.

KRAS-addicted lung cancer cells need αvβ3/galectin-3 to maintain low ROS levels. KRAS-addicted lung cancer cells need αvβ3/galectin-3 to maintain low ROS.

GCS-100 selectively kills KRAS-addicted lung tumors.

AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. A,

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

Greater influx of PMNs and ST using PEGPH20/shIDO-ST.

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

SCLC in CMV TKO mice arises from an alternative cell of origin.

Phenotyping of T cells. Phenotyping of T cells. Circulating lymphocytes from a tumor-naïve C57BL/6 mice (left column) were compared with those from C57BL/6.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Presentation transcript:

Rapamycin decreases PD-L1 expression in lung tumors in vivo. Rapamycin decreases PD-L1 expression in lung tumors in vivo. Immunohistochemical staining for pS6 or PD-L1 in lung tumors treated with vehicle or rapamycin from A/J mice exposed to the tobacco-carcinogen NNK (A), C57BL/6 KRAS LA2 mice (B), or dox-exposed FVB mEGFR+/CC10+ littermates (C). Bar graphs quantify decreased staining of pS6 and PD-L1. Scale bar, 10 μm. *, P ≤ 0.05 by unpaired Student t test. Kristin J. Lastwika et al. Cancer Res 2016;76:227-238 ©2016 by American Association for Cancer Research